{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975806",
  "id": "02975806",
  "pages": 44,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0943",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mf720y5x85kf.pdf",
  "summary": "### **Material Information Summary: Capital Raising Announcement**  \n\n#### **1. Offer Structure**  \n- **Share Purchase Plan (SPP)**:  \n  - **Target Raise**: $2.5 million (AUD).  \n  - **Over-Subscriptions**: Additional $7.5 million (up to $10.0 million total).  \n  - **SPP Shortfall Offer**: Unsubscribed shares may be placed with institutional investors.  \n\n#### **2. Pricing**  \n- **SPP Offer Price**: The lower of:  \n  - Fixed price of **$0.23** (Placement Offer Price), or  \n  - 5% discount to the 5-day VWAP before the Closing Date (rounded to nearest half-cent).  \n\n#### **3. Key Dates**  \n- **Record Date**: 22 July 2025 (7:00 PM Melbourne time).  \n- **Opening Date**: 1 August 2025.  \n- **Closing Date**: 22 August 2025 (5:00 PM Melbourne time).  \n- **Results Announcement**: 26 August 2025.  \n- **AGM Date**: 27 August 2025 (SPP conditional on shareholder approval).  \n- **Trading of New Shares**: Expected 1 September 2025.  \n\n#### **4. Capital Structure Impact**  \n- **Current Shares Outstanding**: 486,477,023 (post-Unconditional Placement).  \n- **Maximum New Shares Under SPP**: ~43.5 million (if $10.0 million raised at $0.23).  \n- **Market Cap at $0.23**: Up to **$124.6 million** (if SPP reaches cap).  \n\n#### **5. Use of Proceeds**  \n- **Primary Allocation**:  \n  - Clinical trials (ACCENT, AMPLICITY, kRAS, OVARIAN): ~$30.0 million.  \n  - Manufacturing (CMC): $6.0 million.  \n  - Working capital/offer costs: $6.7 million.  \n\n#### **6. Risks Highlighted**  \n- Clinical trial failures, regulatory hurdles, R&D tax rebate dependency, and liquidity risks.  \n\n#### **7. Other Key Points**  \n- **Lead Manager**: Bell Potter Securities (not underwritten).  \n- **No brokerage/stamp duty** for SPP participants.  \n- **Scale-back**: May apply to maintain shareholder proportional ownership.  \n\n### **Conclusion**  \nThe SPP offers eligible shareholders a chance to participate at a discounted price, with potential dilution for non-participants. Key risks include trial outcomes and funding sustainability. No material operational updates beyond the capital raise.",
  "usage": {
    "prompt_tokens": 24146,
    "completion_tokens": 555,
    "total_tokens": 24701,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T23:58:33.450187"
}